image
Healthcare - Biotechnology - NASDAQ - US
$ 2.439
0.308 %
$ 3.76 M
Market Cap
-0.95
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one XBIO stock under the worst case scenario is HIDDEN Compared to the current market price of 2.44 USD, Xenetic Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one XBIO stock under the base case scenario is HIDDEN Compared to the current market price of 2.44 USD, Xenetic Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one XBIO stock under the best case scenario is HIDDEN Compared to the current market price of 2.44 USD, Xenetic Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart XBIO

image
$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
2.5 M REVENUE
-1.56%
-4.2 M OPERATING INCOME
6.89%
-3.96 M NET INCOME
4.22%
-2.82 M OPERATING CASH FLOW
31.52%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
649 K REVENUE
5.63%
-1.1 M OPERATING INCOME
-120.06%
-1.05 M NET INCOME
-141.49%
-674 K OPERATING CASH FLOW
-46.83%
0 INVESTING CASH FLOW
0.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Xenetic Biosciences, Inc.
image
Current Assets 6.59 M
Cash & Short-Term Investments 6.17 M
Receivables 0
Other Current Assets 422 K
Non-Current Assets 314 K
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 314 K
89.34 %6.11 %4.55 %Total Assets$6.9m
Current Liabilities 894 K
Accounts Payable 284 K
Short-Term Debt 0
Other Current Liabilities 611 K
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
31.71 %68.29 %Total Liabilities$894.3k
EFFICIENCY
Earnings Waterfall Xenetic Biosciences, Inc.
image
Revenue 2.5 M
Cost Of Revenue 0
Gross Profit 2.5 M
Operating Expenses 6.7 M
Operating Income -4.2 M
Other Expenses -244 K
Net Income -3.96 M
3m3m2m2m1m1m00(1m)(1m)(2m)(2m)(3m)(3m)(4m)(4m)(5m)(5m)3m03m(7m)(4m)244k(4m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-168.16% OPERATING MARGIN
-168.16%
-158.39% NET MARGIN
-158.39%
-65.93% ROE
-65.93%
-57.38% ROA
-57.38%
-69.99% ROIC
-69.99%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Xenetic Biosciences, Inc.
image
2m2m00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -3.96 M
Depreciation & Amortization 0
Capital Expenditures 0
Stock-Based Compensation 172 K
Change in Working Capital 971 K
Others 886 K
Free Cash Flow -2.82 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Xenetic Biosciences, Inc.
image
XBIO has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 15
6. Ownership
Insider Ownership Xenetic Biosciences, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Watch the "What This Means" video here FRAMINGHAM, MA / ACCESS Newswire / April 9, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing difficult to treat cancers, today announced that  Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a  Virtual Investor "What This Means" segment . As part of the segment, Dr. Bissonnette discussed key highlights from the Company's recent poster presentation titled, "DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma," which was presented at the at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting. accessnewswire.com - 3 weeks ago
Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / March 26, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. ("PeriNess"), has entered into a Clinical Study Agreement (the "Agreement") to support an exploratory clinical study of Xenetic's systemic DNase I candidate, XBIO-015, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma. accessnewswire.com - 1 month ago
Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results Encouraging preclinical data supporting the use of DNase-based technology to target NETosis and address difficult to treat cancers Strategic focus on exploratory investigator-initiated clinical studies with institutional partners Continued progress of DNase I development program towards IND and first-in-human study for treatment of pancreatic carcinoma FRAMINGHAM, MA / ACCESS Newswire / March 19, 2025 / Xenetic Biosciences, Inc.  (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2024. Recent Highlights Extended its collaborations with the University of Virginia and Scripps Research through 2025; Entered into a Clinical Trial Services Agreement with PeriNess Ltd. accessnewswire.com - 1 month ago
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not only facilitates increased T cell infiltration but also restores T cell functionality, paving the way for more effective cancer treatment strategies FRAMINGHAM, MA / ACCESS Newswire / March 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster titled, " DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma ," was presented on behalf of the Company by Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute, at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually. accessnewswire.com - 1 month ago
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.  Details for the presentation are as follows:   Abstract Number:  123 Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma Presenter:  Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute Date & Time:  Wednesday, March 12, 2025 at 5:10 p.m. accessnewswire.com - 2 months ago
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment Reid Bissonnette, Ph.D, Executive Consultant for Translational Research and Development at Xenetic, discusses extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform Watch the "What This Means" video here FRAMINGHAM, MA / ACCESSWIRE / December 17, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment As part of the segment, Dr. Bissonnette discussed the Company's recently announced extension of its Research Agreement with the University of Virginia for the advancement of its DNase-Based oncology platform. The Virtual Investor "What This Means" segment featuring Xenetic is now available here. accesswire.com - 4 months ago
Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform Company continuing to advance DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 16, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has extended its previously announced Research Funding Agreement (the "Agreement") with the University of Virginia ("UVA") to advance the development of its systemic DNase program through 2025. Xenetic's DNase-based oncology platform is designed to target neutrophil extracellular traps (NETs), which are weblike structures composed of extracellular chromatin coated with histones and other proteins. accesswire.com - 4 months ago
Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program Collaboration utilizes PeriNess' expertise in clinical development of human recombinant DNase and bolsters efforts towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / December 5, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat cancers, today announced it has entered into a Clinical Trial Services Agreement (the "Agreement") with the Israel-based biotechnology company PeriNess Ltd. ("PeriNess") to advance the Company's development program for its systemic DNase I candidate in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other locally advanced or metastatic solid tumors toward exploratory clinical studies. accesswire.com - 4 months ago
Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting Watch the "What This Means" video here FRAMINGHAM, MA / ACCESSWIRE / November 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic participated in a Virtual Investor "What This Means" segment. As part of the segment, Dr. Bissonnette discussed key highlights from the Company's recent positive data demonstrating DNase I significantly improves efficacy of anti-CTLA-4 immune checkpoint blockade in preclinical models of microsatellite stable/mismatch repair proficient (MSS/MMRp) colorectal carcinoma (CRC) which was presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. accesswire.com - 5 months ago
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer Results bolster Company's rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR T cell therapy FRAMINGHAM, MA / ACCESSWIRE / November 21, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis. The poster titled, " The synergistic action of DNase I and CAR T cells enhances the therapeutic efficacy of adoptive immunotherapy in the syngeneic murine metastasis model ," was presented on behalf of the Company by Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute, at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer, held November 17-20, 2024, in Boston. accesswire.com - 5 months ago
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indications Ongoing progress towards first in human clinical study for locally advanced or metastatic solid tumors Strategic focus on exploratory investigator-initiated studies with institutional partners Ended the quarter with $6.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of 2024. "Over the course of the past quarter, we have continued to make progress advancing our DNase platform. accesswire.com - 5 months ago
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models Data presented at Society for Immunotherapy of Cancer (SITC) 2024 Systemic DNase I combined with 𝛼-CTLA-4 antibody demonstrated to promote antitumor immunity and generate immunological memory against microsatellite stable, mismatch repair proficient colorectal carcinoma (CRC) tumors FRAMINGHAM, MA / ACCESSWIRE / November 12, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced the presentation of positive preclinical data. The poster titled, " DNase I Targeting of Neutrophil Extracellular Traps Improves CTLA-4 Immune Checkpoint blockade in Models of MSS/MMRp CRC ," was presented byReid Bissonnette, Ph.D. accesswire.com - 5 months ago
8. Profile Summary

Xenetic Biosciences, Inc. XBIO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.76 M
Dividend Yield 0.00%
Description Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Contact 40 Speen Street, Framingham, MA, 01701 https://www.xeneticbio.com
IPO Date June 30, 2016
Employees 2
Officers Mr. James F. Parslow Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer & Corporate Secretary